Canadian manufacturer Sernova has reported positive results from an interim analysis of a Phase I/II clinical trial assessing its Cell Pouch transplanted with islet cells in type 1 diabetes patients.

Cell Pouch is an implantable and scalable medical device that forms a natural environment in the body to house therapeutic cells and enable their long-term survival and function.

In the first trial subject, the device transplanted with islet cells met primary safety measures and clinically significant efficacy outcomes, including glucose-stimulated C-peptide and production of insulin.

Results showed no incidences of Cell Pouch-related adverse events. The device was also observed to be well-incorporated with vascularised tissue.

A 6.35kg weight reduction was found, along with stabilising improvements in all glycaemic control measures. Data further revealed a 87.5% decrease in hypoglycemic events from baseline over a monitoring period of two weeks.

In addition, stimulated blood levels of C-peptide and insulin were observed at the 90-day post-transplant point.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Principal study investigator Dr Piotr Witkowski said: “The first of two doses of islets transplanted into the Cell Pouch is showing safety and early indicators of efficacy.

“Importantly, demonstration of glucose-stimulated C-peptide and insulin present in the bloodstream is definitive proof of islet survival and function in the Cell Pouch.”

The non-randomised, unblinded, single arm Phase I/II trial is designed for patients with hypoglycaemia unawareness.

Once vascularised tissue chambers are developed within the implanted Cell Pouches, patients are stabilised on immunosuppression and then purified islets are transplanted into the device.

The primary objective of the trial is safety and tolerability of islet transplantation into the Cell Pouch, followed by efficacy as evaluated using certain defined measures.